Senti Biosciences Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22,000 | $0 | $2.6M | $4.3M | $2.8M |
| Research and development | $37.6M | $34.4M | $32.1M | $28.1M | $22.0M |
| Operating expenses | $68.8M | $61.0M | $95.3M | $66.4M | $43.2M |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$62.1M | -$40.4M |
| Income tax expense | $0 | $0 | — | — | $0 |
| Net income | -$61.4M | -$52.8M | -$71.1M | -$58.2M | -$55.3M |
| Balance Sheet | |||||
| Cash and equivalents | $16.4M | $48.3M | $35.9M | $57.6M | $56.0M |
| Current assets | $23.3M | $59.0M | $71.2M | $102.6M | $60.2M |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M |
| Current liabilities | $14.0M | $13.1M | $12.7M | $18.1M | $14.5M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M |
| Stockholders' equity | $5.6M | $25.6M | $66.9M | $127.3M | -$111.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$43.4M | -$41.4M | -$52.4M | -$34.9M | -$34.6M |
| Depreciation and amortization | $3.6M | $3.8M | $3.6M | $1.4M | $769,000 |
| Stock-based compensation | $5.7M | $1.8M | $9.7M | $16.4M | $2.3M |
| Capital expenditure | $196,000 | $26,000 | $12.0M | $41.4M | $5.5M |
| Free cash flow | -$43.6M | -$41.4M | -$64.4M | -$76.3M | -$40.2M |
| Impairments | $5.1M | $313,000 | $26.0M | $0 | $22,000 |
Shares outstanding 31.1M
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.